ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, ...
LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced ...
Atomizer Ordered and 60% Savings Achieved For Argon Recycling Investment ~Highlights: A$9M capital saving secured – Revised Argon project ...
– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee – – In four out of five pending patients, MRD negativity in bone marrow ...
A new wave of investment from the Middle East into Latin America is reshaping cross-regional capital flows and creating openings across several strategic sectors, according to a new analysis by White ...
SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...
According to the Financial Times, Anthropic is exploring a 2026 IPO. OpenAI’s later timeline may shape investor choices in AI leadership. Trump "peace deal" falls apart Which college football teams ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback